Report Code: A03913 | Pages: NA | Mar 2023 | 6116 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Biologics Market
Request Now !Biologics are the genetically engineered proteins derived from human genes. These are composed of sugars, proteins or nucleic acids or complex combination of these substances. The biologic drugs are derived from a variety of natural sources such as humans, animals, or microorganisms. These drugs are widely used in the treatment of rheumatoid arthritis, anemia, cancer, and other diseases. The products offered by the global biologics market include vaccines, blood and blood components, allergenics, somatic cells gene therapy, tissues, and recombinant therapeutic proteins.
Rise in incidences of chronic diseases, loss of patent extensions of branded drugs, and the increased availability of advanced diagnostics is expected to boost the growth of biologics market. In addition, growth in technology for the production of biologics is projected to fuel the market growth. However, difficulty in manufacturing biologic drugs and the process involved in maintenance, which includes preventing from environmental contamination, maintaining refrigeration processes, and others hinder the market. The increase in demand for advanced diagnostics in treatment purposes and the loss of patent extensions of branded drugs provide opportunity for the growth of global biologics market.
The market is segmented based on product type, therapeutics, source of material, and geography. Based on product type, it is divided into monoclonal antibodies (MAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, blood factors and anticoagulants, vaccines, blood and blood products, allergenic extracts, human cells and tissues, proteins, gene therapies, cellular therapies, and xenotransplantation products. The market on the basis of therapeutics is classified into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. By source material, it is categorized into humans, avian cell culture, yeast, bacteria, insects cell culture, and transgenics. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players in the global biologics market include F. Hoffmann-La Roche AG, Sanofi, Eli Lilly & Company, GSK Biologicals SA, Becton, Dickinson & Company, AstraZeneca plc, Bayer AG, Pfizer Inc, Novartis AG, and Merck KGaA.
Key Benefits :
Biologics Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Therapeutics |
|
By Source Material |
|
By Region |
|
Key Market Players | F. Hoffmann La Roche AG, Sanofi, Eli Lilly and Company, GSK, Biologicals SA, Becton, Dickinson and Company, AstraZeneca plc, Bayer AG, Pfizer Inc, Novartis AG, Merck KGaA |
Loading Table Of Content...
Start reading.
This Report and over 19,654+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers